Sugi Predict

Sugi Predict / Compounds / SCHEMBL29445601

SCHEMBL29445601

SCHEMBL29445601

O=C(CCSC(c1ccccc1)(c1ccccc1)c1ccccc1)NCc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.58
▸ KIF11 P52732 2/20 0.58
▸ KMT2A Q03164 3/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ ALDH1A1 P00352 2/20 0.53
▸ HTT P42858 2/20 0.53
▸ TP53 P04637 1/20 0.51
▸ TSHR P16473 3/20 0.50
▸ EPHX2 P34913 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ POLB P06746 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ TRPV1 Q8NER1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23353436 0.81 HDAC1 (0.51) KIF11
SCHEMBL23299724 0.81 KIF11 (0.47) KIF11HTTL3MBTL1HPGD
SCHEMBL18704720 0.81 KIF11 (0.56) KIF11
SCHEMBL15678807 0.80 GAA (0.70) GAAKMT2AMEN1ALDH1A1HTT
SCHEMBL9517546 0.80 GAA (0.70) GAAKMT2AMEN1ALDH1A1HTT
SCHEMBL12603444 0.80 KIF11 (0.58) KIF11
SCHEMBL2830189 0.79 SMN1; SMN2 (0.45) GAAKIF11ALDH1A1HTTTSHR
SCHEMBL23299725 0.79 KIF11 (0.46) KIF11
SCHEMBL23299715 0.78 LMNA (0.52) KIF11TSHRL3MBTL1HPGD
SCHEMBL19903787 0.78 HPGD (0.52) KIF11ALDH1A1HTTTSHREPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492225-B2 Melanocyte-regulating peptides IDP DISCOVERY PHARMA, S.L. (ES) 2025-12-09 — — US disclosed
EP-4532513-A1 CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS Fundación Privada Instituto De Salud Global Barcelona (ES) 2025-04-09 — — EP disclosed
CN-119451974-A Cyclic peptides having antibacterial activity against Multiple Drug Resistant (MDR) pathogens 巴塞罗那全球健康研究所私人基金会 2025-02-14 — — CN disclosed
US-20240294573-A1 CONSTRAINED PEPTIDES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-09-05 — — US disclosed
US-20240083943-A1 VEGF-REGULATING PEPTIDES IDP DISCOVERY PHARMA, S.L. (ES) 2024-03-14 — — US disclosed
WO-2023227771-A1 CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS Fundación Privada Instituto De Salud Global Barcelona (ES) 2023-11-30 — — WO disclosed
EP-4271480-A1 VEGF-REGULATING PEPTIDES IDP Discovery Pharma, S.L. (ES) 2023-11-08 — — EP disclosed
CN-111263768-B anticancer peptides IDP研发制药有限公司 2023-10-13 — — CN disclosed
EP-3159352-B1 STITCHED POLYPEPTIDES HARVARD COLLEGE (US) 2023-08-02 — — EP disclosed
CN-109071622-B Peptides with anticancer activity IDP研发制药有限公司（ES） 2023-01-13 — — CN disclosed
US-11440939-B2 Anticancer peptides IDP DISCOVERY PHARMA, S.L. (ES) 2022-09-13 — — US disclosed
EP-4039698-A1 PEPTIDES WITH ANTI-CANCER ACTIVITY IDP Discovery Pharma, S.L. (ES) 2022-08-10 — — EP disclosed
WO-2022144401-A1 VEGF-REGULATING PEPTIDES IDP DISCOVERY PHARMA, S.L. (ES) 2022-07-07 — — WO disclosed
EP-4023295-A1 VEGF-REGULATING PEPTIDES IDP Discovery Pharma, S.L. (ES) 2022-07-06 — — EP disclosed
EP-4007563-A1 MELANOCYTE-REGULATING PEPTIDES IDP Discovery Pharma, S.L. (ES) 2022-06-08 — — EP disclosed
US-11352395-B2 Anticancer peptides IDP DISCOVERY PHARMA, S.L. (ES) 2022-06-07 — — US disclosed
EP-3986914-A1 CONSTRAINED PEPTIDES TearSolutions, Inc. (US) 2022-04-27 — — EP disclosed
CN-114245800-A Melanocyte regulatory peptides IDP研发制药有限公司 2022-03-25 — — CN disclosed
US-11279734-B2 Solution-phase affinity selection of inhibitors from combinatorial peptide libraries MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-03-22 — — US disclosed
CN-114206916-A Restricted peptides 缇尔索卢森公司 2022-03-18 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12492225-B2 Melanocyte-regulating peptides MC1R, MITF, MCHR1 GAA 3391/4885KIF11 3284/4885KMT2A 995/4885
US-11440939-B2 Anticancer peptides NGLY1, SLC1A5, SSTR5 GAA 4697/4885KIF11 1241/4885KMT2A 2923/4885
US-11279734-B2 Solution-phase affinity selection of inhibitors from combinatorial peptide libraries TP53, MDM2, MDM4 GAA 3341/4885KIF11 2788/4885KMT2A 3182/4885
US-20240294573-A1 CONSTRAINED PEPTIDES IAPP, NGLY1, VIP GAA 2628/4885KIF11 2210/4885KMT2A 4628/4885
US-11352395-B2 Anticancer peptides PNISR, NGLY1, SLC1A5 GAA 4519/4885KIF11 1612/4885KMT2A 1904/4885
US-20240083943-A1 VEGF-REGULATING PEPTIDES VEGFA, FLT4, FLT1 GAA 4691/4885KIF11 1692/4885KMT2A 3448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.